Tie2 kinase inhibitor

Research use only, not for human use.

Tie2 kinase inhibitor is an optimized compound of SB-203580, selective to Tie2 with IC50 of 0.25 μM.

Tie2 kinase inhibitor is an optimized compound of SB-203580, selective to Tie2 with IC50 of 0.25 μM, 200-fold more potent than p38.

Tie2 kinase inhibitor 1 (compound 5) has an IC50 of 50 μM for p38 and has moderate to excellent cellular activities (cell IC50=232 nM). Tie2 kinase inhibitor 1 inhibits tunica internal endothelial cell kinase 2 (Tie2).

Tie2 kinase inhibitor 1 (intraperitoneally; 50 mg/kg; twice a week for 6 weeks) results in statistically significant reductions in tumor volume by day 15. Tie2 kinase inhibitor 1 results in a 61% reduction in tumor volume by day 20, and reduces tumor volume by 45% by 6 weeks. Animal Model:Athymic nude mice (6- to 8-week-old females)Dosage:50 mg/kg Administration:Intraperitoneally; twice a week for 6 weeks Result:Resulted in statistically significant reductions in tumor volume.

Tunica Interna Endothelial Cell Kinase 2 Inhibitor

Tyrosine Kinase

Tie-2

Tie-2

Cancer

——

948557-43-5

439.53

C26H21N3O2S

>98% (HPLC)

DMSO:35 mg/mL (79.63 mM); Ethanol:<1 mg/mL (<1 mM); Water:<1 mg/mL (<1 mM)

O=S(C1=CC=C(C2=NC(C3=CC=C4C=C(OC)C=CC4=C3)=C(C5=CC=NC=C5)N2)C=C1)C

4-[4-(6-Methoxy-2-naphthalenyl)-2-[4-(methylsulfinyl)phenyl]-1H-imidazol-5-yl]pyridine

(-20℃)

With Ice Pack

≥ 2 years